Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
8 studies found for:    "Subcutaneous panniculitis-like T-cell lymphoma"
Show Display Options
Rank Status Study
1 Active, not recruiting Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas
Conditions: T-Cell Peripheral Lymphoma;   Gamma Delta Hepatosplenic T-Cell Lymphoma;   Subcutaneous Panniculitis-Like T-Cell Lymphoma;   NK T-Cell Lymphoma
Interventions: Biological: Rituximab;   Drug: EPOCH;   Biological: Siplizumab
2 Recruiting CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL
Conditions: Peripheral T-Cell Lymphoma;   Angioimmunoblastic T Cell Lymphoma;   ALK-negative Anaplastic Large Cell Lymphoma;   Enteropathy Associated T Cell Lymphoma;   Subcutaneous Panniculitis Like T Cell Lymphoma;   Acute Adult T-Cell Leukemia/Lymphoma
Interventions: Drug: CEOP/IVE/GDP chemotherapy regimen;   Drug: CEOP chemotherapy regimen for 6 cycles
3 Recruiting CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma
Conditions: ALK-negative Anaplastic Large Cell Lymphoma;   Peripherial T Cell Lymphoma,Not Otherwise Specified;   Angioimmunoblastic T Cell Lymphoma;   Enteropathy Associated T Cell Lymphoma;   Hepatosplenic T Cell Lymphoma;   Subcutaneous Panniculitis Like T Cell Lymphoma
Interventions: Drug: Cyclophosphamide 750mg/m2;   Drug: Vincristine 1.4mg/m2;   Drug: Doxorubicin 50mg/m2;   Drug: prednisone 60mg/m2;   Drug: ifosfamide 2000mg/m2;   Drug: pirarubicin 50mg/m2;   Drug: pirarubicin 25mg/m2;   Drug: Etoposide phosphate 100mg/m2;   Drug: methotrexate 1500mg/m2
4 Recruiting Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma
Conditions: Adult Nasal Type Extranodal NK/T-Cell Lymphoma;   Adult T-Cell Leukemia/Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-Cell Lymphoma;   B Lymphoblastic Leukemia/Lymphoma;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Burkitt Leukemia;   Central Nervous System Lymphoma;   Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma;   Diffuse Large B-Cell Lymphoma;   Enteropathy-Associated T-Cell Lymphoma;   Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Grade 1 Follicular Lymphoma;   Grade 2 Follicular Lymphoma;   Grade 3 Follicular Lymphoma;   Hepatosplenic T-Cell Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle Cell Lymphoma;   Mediastinal (Thymic) Large B-Cell Lymphoma;   Mycosis Fungoides;   Nasal Type Extranodal NK/T-Cell Lymphoma;   Nodal Marginal Zone Lymphoma;   Peripheral T-Cell Lymphoma, Not Otherwise Specified;   Post-Transplant Lymphoproliferative Disorder;   Primary Cutaneous Anaplastic Large Cell Lymphoma;   Primary Effusion Lymphoma;   Sezary Syndrome;   Splenic Marginal Zone Lymphoma;   Subcutaneous Panniculitis-Like T-Cell Lymphoma;   Systemic Anaplastic Large Cell Lymphoma;   T Lymphoblastic Leukemia/Lymphoma;   Transformed Recurrent Non-Hodgkin Lymphoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Dietary Supplement: Salvia hispanica Seed
5 Recruiting Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency
Conditions: Aggressive Non-Hodgkin Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-Cell Lymphoma;   Chronic Lymphocytic Leukemia;   Diffuse Large B-Cell Lymphoma;   Enteropathy-Associated T-Cell Lymphoma;   Hepatosplenic T-Cell Lymphoma;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Mediastinal (Thymic) Large B-Cell Lymphoma;   Nasal Type Extranodal NK/T-Cell Lymphoma;   Peripheral T-Cell Lymphoma, Not Otherwise Specified;   Primary Cutaneous Anaplastic Large Cell Lymphoma;   Refractory Anaplastic Large Cell Lymphoma;   Small Lymphocytic Lymphoma;   Subcutaneous Panniculitis-Like T-Cell Lymphoma
Interventions: Dietary Supplement: Cholecalciferol;   Other: Laboratory Biomarker Analysis
6 Terminated Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma
Conditions: 714leukemia;   Lymphoma
Interventions: Drug: Bortezomib;   Drug: Everolimus
7 Terminated
Has Results
Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Drug: Vorinostat;   Drug: Bortezomib
8 Completed
Has Results
SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Drug: Zolinza (vorinostat);   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone

Study has passed its completion date and status has not been verified in more than two years.